<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865215</url>
  </required_header>
  <id_info>
    <org_study_id>R05-1383</org_study_id>
    <nct_id>NCT00865215</nct_id>
  </id_info>
  <brief_title>A Relative Bioavailability Study of Propranolol Hydrochloride 160 mg Tablets Under Fasting Conditions</brief_title>
  <official_title>A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended Release Capsules Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actavis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actavis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is TO compare the relative bioavailability of Propranolol&#xD;
      Hydrochloride Extended Release Capsules 160 mg (Actavis) with that of INDERAL® LA 160 mg&#xD;
      Capsules (Wyeth Pharmaceuticals) following a single oral dose (1 x 160 mg) in healthy adult&#xD;
      volunteers under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Type: Interventional Study Design: Randomized, single dose, two-way crossover study&#xD;
      under fasting conditions&#xD;
&#xD;
      Official Title: A Relative Bioavailability Study of 160 mg Propranolol Hydrochloride Extended&#xD;
      Release Capsules Under Fasting Conditions&#xD;
&#xD;
      Further study details as provided by Actavis Elizabeth LLC:&#xD;
&#xD;
      Primary Outcome Measures:&#xD;
&#xD;
      Rate and Extend of Absorption&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate and Extend of Absorption</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol Hydrochloride Extended Release Capsules 160 mg, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>INDERAL® LA 160 mg Capsules, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol Hydrochloride Extended Release Capsules 160 mg</intervention_name>
    <description>A: Experimental Subjects received Actavis formulated products under fasting conditions</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Propranolol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INDERAL® LA 160 mg Capsules, single dose</intervention_name>
    <description>B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Propranolol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteers who have been informed of the nature of the study and agree to read, review&#xD;
             and sign the informed consent document prior to Period I dosing.&#xD;
&#xD;
          2. Volunteers who have completed the screening process within 28 days prior to Period I&#xD;
             dosing.&#xD;
&#xD;
          3. Volunteers who are healthy adult men and women 18 to 50 years of age, inclusive, at&#xD;
             the time of dosing.&#xD;
&#xD;
          4. Volunteers who have a body mass index (BMI) between 18-32 kg/m2, inclusive, and weigh&#xD;
             at least 110 lbs.&#xD;
&#xD;
          5. Volunteers who are healthy as documented by the medical history, physical examination&#xD;
             (including but may not be limited to an evaluation of the cardiovascular,&#xD;
             gastrointestinal, respiratory and central nervous systems), vital sign assessments,&#xD;
             12-lead electrocardiogram (ECG), clinical laboratory assessments, and by general&#xD;
             observations. Any abnormalities/deviations from the normal range that might be&#xD;
             considered clinically relevant by the study physician and investigator will be&#xD;
             evaluated for individual cases, documented in study files, and agreed upon by both the&#xD;
             study physician and investigator prior to enrolling the volunteer in this study and&#xD;
             for continued enrollment.&#xD;
&#xD;
          6. Volunteers who have a negative urine drug screen.&#xD;
&#xD;
          7. Female volunteers must have a negative pregnancy screen.&#xD;
&#xD;
          8. Female volunteers practicing an acceptable method of birth control as judged by the&#xD;
             investigator(s), such as condom with spermicide, diaphragm with spermicide,&#xD;
             intrauterine device (IUD), or abstinence throughout the duration of the study; or of&#xD;
             postmenopausal (no menses) status for at least 1 year; or surgically sterile&#xD;
             (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Volunteers who report receiving any investigational drug within 28 days prior to&#xD;
             Period I dosing.&#xD;
&#xD;
          2. Volunteers who report any presence or history of a clinically significant disorder&#xD;
             involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic,&#xD;
             hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined&#xD;
             by the clinical investigator(s).&#xD;
&#xD;
          3. Volunteers whose clinical laboratory test values outside the accepted reference range&#xD;
             and when confirmed on re-examination is deemed to be clinically significant.&#xD;
&#xD;
          4. Volunteers who demonstrate a reactive screen for hepatitis B surface antigen,&#xD;
             hepatitis C antibody, or HIV antibody.&#xD;
&#xD;
          5. Volunteers who report a history of allergic response(s) to propranolol or related&#xD;
             drugs.&#xD;
&#xD;
          6. Volunteers who report the use of any systemic prescription medication in the 14 days&#xD;
             prior to Period I dosing.&#xD;
&#xD;
          7. Volunteers who report the use of any drug known to induce or inhibit hepatic drug&#xD;
             metabolism in the 28 days prior to Period I dosing.&#xD;
&#xD;
          8. Volunteers who report a history of clinically significant allergies including drug&#xD;
             allergies.&#xD;
&#xD;
          9. Volunteers who report a clinically significant illness during the 4 weeks prior to&#xD;
             Period I dosing (as determined by the clinical investigators).&#xD;
&#xD;
         10. Volunteers who report a history of drug or alcohol addiction or abuse within the past&#xD;
             year.&#xD;
&#xD;
         11. Volunteers who demonstrate a positive drug abuse screen for this study prior to Period&#xD;
             I dose administration.&#xD;
&#xD;
         12. Volunteers who currently use tobacco products.&#xD;
&#xD;
         13. Volunteers who report donating greater than 150 mL of blood within 28 days prior to&#xD;
             Period I dosing. All subjects will be advised not to donate blood for four weeks after&#xD;
             completing the study.&#xD;
&#xD;
         14. Volunteers who report donating plasma (e.g. plasmapheresis) within 14 days prior to&#xD;
             Period I dosing. All subjects will be advised not to donate plasma for four weeks&#xD;
             after completing the study.&#xD;
&#xD;
         15. Volunteers who demonstrate a positive pregnancy screen (females only).&#xD;
&#xD;
         16. Volunteers who are currently pregnant or breastfeeding (females only).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D. Carlson,, Pharm.D,</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRACS Institute, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRACS Institute, Ltd.</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>August 13, 2010</last_update_submitted>
  <last_update_submitted_qc>August 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Meena Venugopal, Director, Clinical R&amp;D</name_title>
    <organization>Actavis Inc</organization>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>Propranolol</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

